Delisting risk
aTyr Pharma (ATYR)
Develops efzofitimod and tRNA-synthetase-derived therapies for fibrosis and inflammation.
$0.5000
Pre-market+0.00 (+0.20%)
At close$0.4990(+4.72%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Insiders5 holders · as of May 28, 2026 | 1.03% | 1.01M shares | |
| Strategic holders3 holders · as of Jun 5, 2026 | 22.68% | 22.24M shares | |
| Otherremainder | 76.29% | 74.83M shares |
98.09M company shares as of Sep 3, 2026 · holders as of their latest filing
Institutions13F
No 13F holders on record.
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Federated Hermes, Inc. | 10.76% | 10.54M | 13G | Oct 7, 2025 ↗ |
| BlackRock, Inc. | 6.50% | 5.76M | 13G | Jul 17, 2025 ↗ |
| Point72 Capital Advisors, Inc.incl. Steven A. Cohen, Point72 Asset Management, L.P. | 6.20% | 5.04M | 13G | Oct 15, 2024 ↗ |
| FMR LLC | 6.10% | 5.94M | 13G | Jun 5, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| May 27, 2026 | Paul Schimmeldirector | Purchase | 100,000 | $0.4963 | 779,143 |
| Feb 4, 2026 | Nancy Denyesofficer: General Counsel | Sale | 1,118 | $0.9761 | 33,124 |
| Feb 4, 2026 | Jill Marie Broadfootofficer: Chief Financial Officer | Sale | 1,558 | $0.9760 | 37,296 |
| Feb 4, 2026 | Sanjay Shukladirector, officer: President and CEO | Sale | 3,745 | $0.9760 | 153,553 |
| Oct 8, 2025 | Paul Schimmeldirector | Purchase | 682,001 | $0.8980 | 1,095,024 |
| Oct 9, 2025 | Paul Schimmeldirector | Purchase | 317,999 | $0.9414 | 1,413,023 |
CongressHouse and Senate disclosures
Not reported.